natgillin/translations-raw huggingface dataset:
Patients with moderate hepatic impairment (Child-Pugh Class B) showed no evidence of an increase in systemic exposure to either umeclidinium or vilanterol (Cmax and AUC) following administration of umeclidinium/vilanterol with umeclidinium at twice the recommended dose and vilanterol at the recommended dose and no evidence of altered protein binding between patients with moderate hepatic impairment and healthy volunteers.
Pri bolnikih z zmerno okvaro jeter (Child-Pugh B) po uporabi kombinacije umeklidinij/vilanterol (umeklidinij v dvakratnem priporočenem odmerku in vilanterol v priporočenem odmerku) niso ugotovili večje sistemske izpostavljenosti umeklidiniju ali vilanterolu (Cmax in AUC); prav tako pri bolnikih z zmerno okvaro jeter v primerjavi z zdravimi prostovoljci niso ugotovili znakov spremenjene vezave na beljakovine.
Patients with moderate or severe hepatic impairment and those with unexplained persistent abnormal liver function tests.
bolniki z zmerno ali hudo jetrno okvaro in bolniki z nepojasnjenimi, stalno nenormalnimi rezultati preiskav jetrnega delovanja;
Patients with moderate or severe hepatic insufficiency (Child’s-Pugh Class B or C) were excluded from the Phase III studies (Kodiac 4 and 5).
Študiji III. faze (Kodiac 4 in 5) nista vključili bolnikov z zmerno ali hudo odpovedjo jeter (Child-Pugh razred B ali C).
patients with moderate or severe reduction in kidney function or with acute conditions that could potentially alter kidney function such as dehydration, severe infection or shock;
bolnikih z zmerno do hudo okvaro delovanja ledvic ali z akutnimi stanji, ki bi lahko vplivala na delovanje ledvic (na primer dehidracija, huda okužba ali šok);
patients with moderate or severe reductions in kidney function or with acute conditions that could potentially alter kidney function such as dehydration, severe infection or shock;
bolnikih z zmerno do hudo okvaro delovanja ledvic ali z akutnimi stanji, ki bi lahko vplivala na delovanje ledvic (na primer dehidracija, huda okužba ali šok);
Patients with moderate or severe renal impairment require a dose adjustment of emtricitabine and tenofovir disoproxil fumarate that cannot be achieved with the combination tablet (see sections 4.2 and 5.2).
Pri bolnikih z zmerno ali hudo ledvično okvaro je potrebna prilagoditev odmerkov emtricitabina in dizoproksiltenofovirijevega fumarata, ki je ni mogoče doseči s kombinirano tableto (glejte poglavji 4.2 in 5.2).
Patients with moderate or severe renal impairment require a dose interval adjustment of emtricitabine and tenofovir disoproxil fumarate that cannot be achieved with the combination tablet (see sections 4.2 and 4.4).
Pri bolnikih z zmerno ali hudo okvaro ledvic je treba prilagoditi interval odmerka emtricitabina in dizoproksiltenofovirijevega fumarata, česar ni mogoče doseči s kombinirano tableto (glejte poglavji 4.2 in 4.4).
Patients with moderate or severe renal impairment require a dose interval adjustment of emtricitabine and tenofovir disoproxil fumarate that cannot be achieved with the combination tablet (see sections 4.2 and 5.2).
Pri bolnikih z zmerno ali hudo ledvično okvaro je treba interval odmerjanja emtricitabina in dizoproksiltenofovirijevega fumarata prilagoditi, česar pa s kombinirano tableto ni mogoče doseči (glejte poglavji 4.2 in 5.2).
Patients with moderate or severe renal impairment require a dose interval adjustment of emtricitabine and tenofovir disoproxil fumarate that cannot be achieved with the combination tablet (see sections 4.4 and 5.2).
Pri bolnikih z zmerno ali hudo ledvično okvaro je treba interval odmerjanja emtricitabina in dizoproksiltenofovirijevega fumarata prilagoditi, česar pa s kombinirano tableto ni mogoče doseči (glejte poglavji 4.4 in 5.2).
Patients with moderate or severe renal impairment require dose interval adjustment of emtricitabine and tenofovir disoproxil fumarate that cannot be achieved with the combination tablet (see sections 4.2 and 4.4).
Pri bolnikih z zmerno ali hudo ledvično insuficienco je potrebna prilagoditev intervala odmerjanja emtricitabina in dizoproksiltenofovirijevega fumarata, ki je ni mogoče doseči s kombinirano tableto (glejte poglavji 4.2 in 4.4).
Patients with moderate or severe renal impairment require dose interval adjustment of emtricitabine and tenofovir disoproxil fumarate that cannot be achieved with the combination tablet (see sections 4.4 and 5.2).
Pri bolnikih z zmerno ali hudo ledvično okvaro je potrebna prilagoditev intervala odmerjanja emtricitabina in dizoproksiltenofovirijevega fumarata, ki je ni mogoče doseči s kombinirano tableto (glejte poglavji 4.4 in 5.2).
Patients with moderate or severe renal impairment were excluded from Kyprolis-lenalidomide combination studies.
Bolniki z zmerno ali hudo okvaro ledvic so bili izključeni iz študij, v katerih so kombinirali zdravilo Kyprolis in lenalidomid.
Patients with moderate renal impairment
bolniki z zmerno ledvično okvaro,
Patients with moderate renal impairment (CrCl 30 to 50 ml/min) who received a reduced dose of 20 mg/m2 twice daily showed no significant increase in mean 5-FU AUC0-inf relative to that of the normal group.
Pri bolnikih z zmerno ledvično okvaro (CrCl 30–50 ml/min), ki so dvakrat dnevno prejemali zmanjšan odmerek 20 mg/m2, niso opazili izrazitega povečanja povprečja AUC0-inf za 5-FU v primerjavi s povprečjem v normalni skupini.
Patients with moderate renal impairment (CrCL between 30 and 50 mL/min) had on average 2.29-fold and 1.81-fold higher pre- and post-dose dabigatran plasma concentrations, respectively, when compared with patients without renal impairment (CrCL ≥ 80 mL/min).
Bolniki z zmerno ledvično okvaro (CrCl 30 do 50 ml/min) so imeli v primerjavi z bolniki brez ledvične okvare (CrCl ≥ 80 ml/min) pred odmerkom in po odmerku povprečno 2,29- oziroma 1,81-krat večje koncentracije dabigatrana v plazmi.
Patients with moderate renal impairment (CrCL between 30-50 mL/min) had on average 2.29-fold and 1.81-fold higher pre- and post-dose dabigatran plasma concentrations, respectively, when compared with patients without renal impairment (CrCL ≥ 80 mL/min).
Bolniki z zmerno ledvično okvaro (CrCl 30 do 50 ml/min) so imeli v primerjavi z bolniki brez ledvične okvare (CrCl ≥ 80 ml/min) pred odmerkom in po odmerku povprečno 2,29- oziroma 1,81-krat večje koncentracije dabigatrana v plazmi.
Patients with moderate renal impairment (creatinine clearance 30 – < 60 ml/min) require a 50% dose reduction (see section 5.2).
Bolniki z zmerno okvaro ledvic (kreatininski očistek 30 – <60 ml/min) potrebujejo 50 % zmanjšanje odmerka (glejte poglavje 5.2).
Patients with moderate renal impairment (creatinine clearance <50 - 30 mL/min) showed a higher exposure to this medicine (see section 5.2).
Pri bolnikih z zmerno ledvično okvaro (očistek kreatinina < 50 - 30 ml/min) je bila izpostavljenost temu zdravilu večja (glejte poglavje 5.2).
Patients with moderate renal impairment had a higher incidence of gastrointestinal and central nervous system-related adverse events, thus these patients generally had lower tolerability of naltrexone / bupropion.
Pri bolnikih z zmerno ledvično okvaro je bila pojavnost neželenih učinkov na prebavila in neželenih učinkov, povezanih s centralnim živčnim sistemom, večja, zato je bila njihova toleranca za naltrekson/bupropion na splošno nižja.
Patients with moderate renal impairment should be more frequently monitored for haematological toxicities.
Bolnike z zmerno ledvično okvaro je treba zaradi hematološke toksičnosti bolj pogosto spremljati.
Patients with moderate renal insufficiency were to receive a lower starting dose of lenalidomide 10 mg daily on the same schedule.
Bolniki z zmerno insuficienco ledvic so prejemali manjši začetni odmerek lenalidomida 10 mg na dan po enakem razporedu.
Patients with moderate to severe CHF (NYHA Class III–IV) (see sections 4.2 and 5.2).
Bolniki z zmernim do hudim CHF (III.–IV. razreda po razvrstitvi NYHA) (glejte poglavji 4.2 in 5.2).
Patients with moderate to severe elevations (ASAT or ALAT > 5 ULN) should be permanently discontinued from nevirapine.
Pri bolnikih z zmerno ali močno povečanimi vrednostmi (AST ali ALT > 5-kratna zgornja mejna normalna vrednost) pa je potrebno nevirapin trajno ukiniti.
Patients with moderate to severe hepatic impairment
Bolniki z zmerno do hudo okvaro jeter
Patients with moderate to severe renal insufficiency, because insufficient clinical experience is available in this patient group,
Bolniki z zmerno do hudo ledvično insuficienco, ker v tej skupini ni dovolj kliničnih izkušenj,
Patients with moderate to severe renal insufficiency, because insufficient clinical experience is available in this patient group.
Bolniki z zmerno do hudo ledvično insuficienco, ker v tej skupini ni dovolj kliničnih izkušenj,
Patients with moderate to severe renal insufficiency, because insufficient clinical experience is available in this patient group.
Bolniki z zmerno do hudo ledvično insuficienco, ker v tej skupini ni dovolj kliničnih izkušenj.
Patients with moderately impaired renal function show an increased rate of dose reduction (44%) vs.
Bolnikom z zmerno ledvično okvaro je bilo pogosteje treba zmanjšati odmerek (44 %) kot bolnikom brez ledvične okvare (33 %) in bolnikom z blago ledvično okvaro (32 %).
patients with moderately or severely reduced kidney function or with severe conditions that could affect the kidneys such as dehydration or severe infection.
bolnikih z zmerno ali močno zmanjšanim delovanjem ledvic ali z resnimi stanji, ki lahko vplivajo na ledvice – na primer dehidracija ali huda okužba;
Patients with mucosal healing at week 6c
Bolniki s celjenjem sluznice v 6. tednuc
Patients with multiple sclerosis
Bolniki z multiplo sklerozo
Patients with myeloid leukaemia or myelodysplastic syndromes
Bolniki z mieloično levkemijo ali mielodisplastičnimi sindromi
patients with myocardial infarction within the last 90 days,
bolniki z miokardnim infarktom v zadnjih 90 dneh,
Patients with naïve use of ENFd
bolniki, ki so prvič jemali ENFd
Patients with newly diagnosed ALL received a single intramuscular injection of Oncaspar (2500 U/m² body surface area) or native asparaginase from E. coli (25000 U/m² body surface area) or from Erwinia (25000 U/m² body surface area).
Bolniki z novo diagnozo ALL so prejeli eno intramuskularno injekcijo zdravila Oncaspar (2.500 e./m² telesne površine) ali nativne asparaginaze iz E. coli (25.000 e./m² telesne površine) ali iz bakterije Erwinia (25.000 e./m² telesne površine).
Patients with newly diagnosed multiple myeloma aged 75 years and older should be carefully assessed before treatment is considered (see section 4.4).
Bolnike z novo diagnosticiranim diseminiranim plazmocitomom, stare 75 let ali več, je treba skrbno oceniti, preden pride v poštev zdravljenje (glejte poglavje 4.4).
Patients with newly diagnosed, or a family history of, familial hypertriglyceridaemia may have poor absorption of cholic acid from the intestine.
Bolniki z novo diagnozo ali družinsko hipertrigliceridemijo v družinski anamnezi imajo lahko slabo absorpcijo holne kisline iz črevesja.
Patients with newly-diagnosed glioblastoma multiforme
Bolniki z novo diagnosticiranim multiformnim glioblastomom:
Patients with nitrite-induced methaemoglobinaemia during treatment of cyanide poisoning
Bolniki z methemoglobinemijo, povzročeno z nitritom med zdravljenjem zastrupitve s cianidom.
Patients with no
pregledani bolniki (%)c
Patients with no deterioration/patients evaluated (%)c
bolniki brez poslabšanja/ pregledani bolniki (%)c
Patients with no M918T mutation and other mutations not tested or negative (n=79)*
Bolniki brez mutacije M918T in brez preskušanja za druge mutacije ali pa so te negativne (n = 79)
Patients with no prior bevacizumab (n (%))
Bolniki, ki predhodno niso bili zdravljeni z bevacizumabom (n (%))
Patients with no prior bevacizumab excluding adjuvant only (n (%))
Bolniki, ki predhodno niso bili zdravljeni z bevacizumabom, izključujoč samo adjuvantno zdravljenje (n (%))
Patients with no prior bevacizumab excluding adjuvant only (n (%))
Bolniki, predhodno zdravljeni z bevacizumabom, izključujoč samo adjuvantno zdravljenje (n (%))
Patients with no/non-naïve use of ENFc
bolniki, ki še niso/niso prvič jemali ENFc
Patients with non-Hodgkin’s lymphoma should then be evaluated for evidence of tumour lysis syndrome including appropriate laboratory tests and, for pulmonary infiltration, with a chest X-ray.
Pri bolnikih z ne-Hodgkinovim limfomom v takem primeru preverimo – vključno z laboratorijskimi testi – možnost pojava sindroma razpada tumorja in pljučno infiltracijo z rentgenskim pregledom prsnega koša.
Patients with Non-Small Cell Lung Cancer:
Bolniki z nedrobnoceličnim rakom pljuč:
Patients with non-valvular atrial fibrillationa)
Bolniki z nevalvularno atrijsko fibrilacijoa)
patients with normal renal or
normalnim delovanjem ledvic ali
Patients with NSCLC should be selected for treatment based on the tumour expression of PD-L1 confirmed by a validated test (see section 5.1).
Bolnike z NSCLC je treba za zdravljenje izbrati na podlagi ekspresije PD-L1, potrjene z validirano preiskavo (glejte poglavje 5.1).
Patients with NYHA functional classification IV
Bolniki, ki so po klasifikaciji NYHA uvrščeni v funkcijski razred IV
Patients with ocular melanoma, primary CNS melanoma and active brain metastases were not included in the pivotal clinical trial (see section 5.1).
Bolniki z očesnim melanomom, s primarnim melanomom v osrednjem živčevju in z aktivnimi zasevki v možganih niso bili vključeni v ključno klinično preskušanje (glejte poglavje 5.1).
Patients with ocular melanoma, primary CNS melanoma, active brain metastases, human immunodeficiency virus (HIV), hepatitis B, and hepatitis C were not included in the pivotal clinical trial.
Bolniki z očesnim melanomom, bolniki s primarnim melanomom v osrednjem živčevju, bolniki z aktivnimi zasevki v možganih, bolniki z okužbo z virusom humane imunske pomanjkljivosti (HIV), bolniki s hepatitisom B in bolniki s hepatitisom C niso bili vključeni v ključno klinično preskušanje.
Patients with ongoing peripheral neuropathy ≥Grade 2 were excluded from clinical studies.
Bolniki s potekajočo periferno nevropatijo ≥ 2. stopnje so bili izključeni iz kliničnih študij.
Patients with ongoing ≥Grade 2 peripheral neuropathy were excluded from clinical studies with pomalidomide.
Bolniki, ki imajo periferno nevropatijo ≥ 2. stopnje, so bili izključeni iz kliničnih študij s pomalidomidom.
Patients with only a mild indirect hyperbilirubinaemia, known or suspected Gilbert’s syndrome, and elevation in ALT > 3 x ULN should be managed as per the recommendations outlined for isolated ALT elevations.
Bolnike z le blago indirektno hiperbilirubinemijo ali z znanim Gilbertovim sindromom ali sumom nanj ter z ALT > 3-kratno ZMN je treba obravnavati po priporočilih, opisanih za primer izoliranega zvišanja ALT.
Patients with only one Event
bolniki s samo enim dogodkom
Patients with operable node-negative breast cancer eligible to receive chemotherapy (GEICAM 9805)
Bolnice z operabilnim rakom dojke s pozitivnimi bezgavkami (TAX 316)
Patients with operable node-positive breast cancer (TAX 316)
Bolniki z operabilnim rakom dojke s pozitivnimi bezgavkami (TAX 316).
patients with other eye conditions such as a detachment of the retina or a hole in the macula.
bolnikov z drugimi očesnimi boleznimi, kot so odstop mrežnice ali luknja v rumeni pegi,
patients with other severe liver problems;
bolnikih z drugimi resnimi težavami z jetri;
Patients with PAH currently have very limited treatment options; therefore there is a high unmet medical need.
Bolniki s PAH imajo trenutno zelo omejene možnosti zdravljenja, zato obstaja velika neizpolnjena zdravstvena potreba.
Patients with pain who receive chronic opioid therapy develop tolerance to respiratory depression and hence the risk of respiratory depression in these patients is reduced.
Bolniki z bolečinami, ki prejemajo kronično opioidno zdravljenje, razvijejo toleranco za depresijo dihanja, zato je tveganje za depresijo dihanja pri teh bolnikih manjše.
Patients with pancreatic cancer:
Bolniki z rakom trebušne slinavke:
Patients with Parkinson’s disease are particularly vulnerable to the adverse effects of hypotension due to existing gait issues.
Bolniki s Parkinsonovo boleznijo so še posebej ranljivi na neželene učinke hipotenzije zaradi obstoječe problematike s hojo.
Patients with penile curvature >90° were not included in the clinical studies.
Bolniki z ukrivljenostjo penisa > 90 ° v klinične študije niso bili vključeni.
Patients with performance status 2 to 4
Bolnice s stanjem zmogljivosti od 2 do 4
Patients with pericardial constriction
bolniki s konstrikcijo perikarda,
patients with peripheral arterial disease (problems with blood flow in the arteries); patients who have a condition known as ‘acute coronary syndrome’, when it should be given with aspirin (another medicine that prevents blood clots), including patients who have had a stent
ki imajo periferno arterijsko bolezen (težave s pretokom krvi v arterijah); ki imajo akutni koronarni sindrom, pri katerem se mora zdravilo dajati skupaj z aspirinom (drugim zdravilom za preprečevanje krvnih strdkov).
patients with peripheral arterial disease (problems with blood flow in the arteries); patients who have a condition known as ‘acute coronary syndrome’, when it should be given with aspirin (another medicine that prevents blood clots), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up).
bolnikom s periferno arterijsko boleznijo (težavami s pretokom krvi v arterijah); bolnikom z akutnim koronarnim sindromom, pri katerih se mora zdravilo dajati skupaj z aspirinom (drugim zdravilom za preprečevanje krvnih strdkov), vključno z bolniki, katerim je bil vstavljen stent (kratka cevka, nameščena v arteriji, da prepreči njeno zapiranje).
patients with peripheral arterial disease (problems with blood flow in the arteries); patients with acute coronary syndrome (a condition in which blood supply to the heart is reduced), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up); the medicine should be given with aspirin (another medicine that prevents blood clots).
bolnikom s periferno arterijsko boleznijo (težavami s pretokom krvi v arterijah); bolnikom z akutnim koronarnim sindromom (stanjem, pri katerem je dotok krvi v srce zmanjšan), vključno z bolniki, katerim je bil vstavljen stent (kratka cevka, nameščena v arterijo, da prepreči njeno zamašitev); zdravilo je treba jemati skupaj z aspirinom (drugim zdravilom, ki preprečuje nastajanje krvnih strdkov).
patients with peripheral arterial disease (problems with blood flow in the arteries); patients with acute coronary syndrome (a condition in which blood supply to the heart is reduced), when it should be given with aspirin (another medicine that prevents blood clots), including patients who have had a stent inserted (a short tube placed in an artery to prevent it closing up).
bolnikom s periferno arterijsko boleznijo (težavami s pretokom krvi v arterijah); bolnikom z akutnim koronarnim sindromom (bolezenskim stanjem, za katerega je značilen zmanjšan dotok krvi v srce) , pri katerih se mora zdravilo dajati skupaj z aspirinom (drugim zdravilom za preprečevanje krvnih strdkov), vključno z bolniki, ki jim je bil vstavljen stent (kratka cevka, nameščena v arteriji, da prepreči njeno zamašitev).
Patients with Permanent Atrial Fibrillation:
Bolniki s permanentno atrijsko fibrilacijo:
Patients with persistent and severe diarrhoea, nausea, loss of appetite, or vomiting should contact their doctor, as they may be at risk of low blood potassium levels and kidney failure.
Bolniki z dolgotrajno in močno drisko, slabostjo, izgubo teka ali bruhanjem morajo poiskati zdravniško pomoč, saj so lahko izpostavljeni tveganju za nizke ravni kalija v krvi in odpoved ledvic.
Patients with PKU have defective versions of the enzyme, and patients with BH4 deficiency have low levels of BH4, a ‘cofactor’ that this enzyme needs to work properly.
Bolniki s fenilketonurijo imajo okvarjeno različico encima, bolniki s pomanjkanjem BH4 pa nizko raven kofaktorja BH4, ki ga encim potrebuje za pravilno delovanje.
Patients with plasma HIV-1 RNA <400 copies/ml, Snapshot analysis
Bolniki s plazemsko HIV-1 RNA < 400 kopij/ml, momentna analiza
Patients with platelet count normalization, n (%)
Bolniki z normalizacijo števila trombocitov, n (%)
Patients with Pompe disease are at risk of respiratory infections due to the progressive effects of the disease on the respiratory muscles.
Pri bolnikih s Pompejevo boleznijo obstaja tveganje za razvoj okužbe dihal zaradi progresivnega učinka bolezni na dihalne mišice.
Patients with poorer tolerability still receive significant benefit if white blood cell cystine levels are below 2 nmol hemicystine/mg protein.
Bolniki, ki slabo prenašajo zdravilo, imajo od njega še vedno pomembne koristi, če so vrednosti cistina v belih krvnih celicah pod 2 nmol hemicistina/mg beljakovin.
Patients with porphyria or a family history of porphyria should be closely monitored during treatment with Pergoveris.
Bolnice s porfirijo ali s porfirijo v družinski anamnezi, moramo med zdravljenjem z zdravilom Pergoveris skrbno nadzorovati.
Patients with Prader-Willi syndrome should not be treated with Valtropin unless they are also suffering from growth hormone failure.
Bolnikov s Prader-Willijevim sindromom se ne sme zdraviti z zdravilom Valtropin, razen če imajo hkrati pomanjkanje rastnega hormona.
Patients with pre- existing helminth infections should be treated before starting therapy.
Bolnike, ki že imajo infestacijo s helminti, je treba zdraviti pred uvedbo zdravila Nucala.
Patients with pre- existing liver disease may be at increased risk of developing elevated liver enzymes when taking teriflunomide and should be closely monitored for signals of liver disease.
Bolniki z obstoječo boleznijo jeter imajo lahko večje tveganje za zvišane ravni jetrnih encimov, če jemljejo teriflunomid, zato jih je treba natančno spremljati glede znakov jetrne bolezni.
Patients with pre-existent hepatic disease (cirrhosis or clinically significantly elevated aminotransferases) and patients using other targeted therapy for PAH (e.g. prostanoids) were excluded.
Bolniki, ki so že imeli bolezen jeter (ciroza ali klinično pomembno zvišanje aktivnosti aminotransferaz) in bolniki, ki so se zdravili z drugo obliko usmerjenega zdravljenja PAH (npr. s prostanoidi), so bili izključeni.
Patients with pre-existent hepatic disease and patients using non- conventional PAH treatments (eg, iloprost) were excluded.
Bolnike z obstoječo boleznijo jeter in bolnike z nekonvencionalnim zdravljenjem PAH (npr. iloprost) so izključili.
Patients with pre-existing enthesopathy (63%) or pre-exisiting dactylitis (42%) were enrolled.
Vključili so bolnike, ki so že prej imeli entezopatijo (63 %) ali daktilitis (42 %).
Patients with pre-existing enthesopathy (63%) or pre-existing dactylitis (42%) were enrolled.
Vključili so bolnike, ki so že prej imeli entezopatijo (63 %) ali daktilitis (42 %).
Patients with pre-existing liver dysfunction including chronic active hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice.
Pri bolnikih z obstoječo motnjo delovanja jeter, vključno s kroničnim aktivnim hepatitisom, je pogostnost nepravilnosti v delovanju jeter med kombiniranim protiretrovirusnim zdravljenjem (CART – combination antiretroviral therapy) večja, zato jih je treba spremljati skladno s standardno prakso.
Patients with pre-existing liver dysfunction, including chronic active hepatitis, can have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Pri bolnikih z obstoječo disfunkcijo jeter se lahko med kombinirano protiretrovirusno terapijo pogosteje pojavijo nepravilnosti delovanja jeter, zato morate takšne bolnike nadzorovati skladno z običajno prakso.